시장보고서
상품코드
1193254

만성 B형 간염 시장 : 약물 클래스별, 성별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2021-2031년)

Chronic Hepatitis B Market By Drug Class, By Gender, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 290 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

만성 B형 간염 세계 시장은 2021년에 45억 8,980만 달러, 2031년에는 62억 1,315만 달러에 이르고, 2022-2031년간 CAGR 3.0%를 나타낼 것으로 예측되고 있습니다.

B형 간염은 간을 공격하는 바이러스 감염으로 급성 질환과 만성 질환을 모두 일으킬 수 있습니다. B형 간염은 B형 간염 바이러스(HBV)로 인한 생명을 위협할 수 있는 간 감염입니다. B형 간염은 만성 감염을 일으켜 간경변이나 간암에 의한 사망 위험을 높인다고 합니다.

B형 간염의 이환율 상승과 B형 간염에 대한 인지도의 향상이 시장 성장을 뒷받침하고 있습니다. 예를 들어 2022년 6월에 발표된 세계보건기구(WHO) 보고서에 따르면 세계에서는 2019년에 추정 2억 9600만명이 만성 B형 간염에 감염되어 매년 150만명이 새롭 에 감염된 것입니다. 따라서 세계적으로 B형 간염의 유병률이 증가하는 것은 시장 성장을 뒷받침한다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19의 영향 분석

제4장 만성 간염(CHB) 시장 : 약효 분류별

  • 개요
    • 시장 규모 및 예측
  • 항바이러스제
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
  • 면역조절제
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별

제5장 만성 간염 B(CHB) 시장 : 남녀별

  • 개요
    • 시장 규모 및 예측
  • 남성
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
    • 남성 만성 B형 간염(CHB) 시장 :연령층별
      • 성인 시장 규모 및 예측 : 지역별
      • 제리아트 시장 규모 추이·예측 : 지역별
  • 여성
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
    • 여성 만성 B형 간염(CHB) 시장 :연령층별
      • 성인 시장 규모 및 예측 : 지역별
      • 제리아트 시장 규모 및 예측 : 지역별

제6장 만성 B형 간염(CHB) 시장 : 유통 채널별

  • 개요
    • 시장 규모 및 예측
  • 병원 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
  • 약국, 소매 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
  • 온라인 제공자
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별

제7장 만성 간염 B(CHB) 시장 : 지역별

  • 개요
    • 시장 규모 및 예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모 및 예측 : 약효 분류별
    • 북미 시장 규모 및 예측 : 남녀별
      • 북미 남성 만성 B형 간염(CHB) 시장 :연령층별
      • 북미 여성 만성 B형 간염(CHB) 시장 :연령층별
    • 북미 시장 규모 및 예측 : 유통채널별
    • 북미 시장 규모 및 예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽 시장 규모 및 예측 : 약물 클래스별
    • 유럽 시장 규모 및 예측 : 남녀별
      • 유럽 남성 만성 B형 간염(CHB) 시장 :연령층별
      • 유럽 여성 만성 B형 간염(CHB) 시장 :연령층별
    • 유럽 시장 규모 및 예측 : 유통 채널별
    • 유럽 시장 규모 및 예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양 시장 규모 및 예측 : 약물 클래스별
    • 아시아태평양 시장 규모 및 예측 : 남녀별
      • 아시아태평양의 남성 만성 B형 간염(CHB) 시장 : 연령층별
      • 아시아태평양의 여성 만성 B형 간염(CHB) 시장 : 연령층별
    • 아시아태평양 시장 규모 및 예측 : 유통 채널별
    • 아시아태평양 시장 규모 및 예측 : 국가별
      • 일본
      • 중국
      • 호주
      • 인도
      • 한국
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA 시장 규모 및 예측 : 약물 클래스별
    • LAMEA 시장 규모 및 예측 : 남녀별
      • LAMEA 남성 만성 B형 간염(CHB) 시장 :연령층별
      • LAMEA 여성 만성 B형 간염(CHB) 시장 : 연령층별
    • LAMEA 시장 규모 및 예측 : 유통채널별
    • LAMEA 시장 규모 및 예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카 공화국
      • LAMEA 기타 지역

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 발전

제9장 기업 프로필

  • GlaxoSmithKline(GSK)
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • Bristol Myers Squibb Co.
  • Teva Pharmaceutical Industries Limited
  • zydus cadila
  • Novartis AG
  • F. Hoffman La Roche, Ltd.
  • Viatris Inc.(Mylan NV)
  • Cipla Ltd
LSH 23.03.28

The global chronic hepatitis B market was valued at $4,589.8 million in 2021 and is projected to reach $6,213.15 million by 2031, registering a CAGR of 3.0% from 2022 to 2031.  Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B can cause chronic infection and increases the risk of death from cirrhosis and liver cancer.

The increase in rate of hepatitis B and rise in awareness about hepatitis B drive the growth of the market. For instance, according to a report of World Health Organization (WHO) published in June 2022, globally, an estimated 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Thus, increase in prevalence of hepatitis B globally boosts the growth of the market.

In addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis B virus transmission. For instance, as per the report of World Health Organization (WHO) published in May 2022, about 118.54 million blood donations are made worldwide. About 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory.

Moreover, increase in R&D activities for development of novel chronic hepatitis B treatment, rise in the U.S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in June 2022, glaxosmithkline (GSK), a science-led global healthcare company, announced the interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks' treatment in people with chronic hepatitis B (CHB). Furthermore, advancements in hepatitis B treatment and rise in diagnosis rate further contribute toward the market growth. However, high cost of chronic hepatitis B drugs is projected to hinder the growth of the market.

The chronic hepatitis B market is segmented on the basis of drug class, gender, distribution channel, and region. By drug class, the market is fragmented into antivirals, and immune modulators. By gender, the market is classified into male, and female. The male segment is further divided into adult and geriatric. The female segment is further divided into adult and geriatric. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Biocon Inc, Cipla Limited, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Novartis AG, Reliance Life Sciences, Sun Pharmaceutical Industries Limited, Teva pharmaceuticals, Viatris Inc and Zydus Cadila.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic hepatitis b (chb) market analysis from 2021 to 2031 to identify the prevailing chronic hepatitis b (chb) market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the chronic hepatitis b (chb) market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global chronic hepatitis b (chb) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Antivirals
  • Immune Modulators

By Gender

  • Male
    • Age Group
    • Adult
    • Geriartic
  • Female
    • Age Group
    • Adult
    • Geriartic

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • GlaxoSmithKline (GSK)
    • Gilead Sciences, Inc.
    • Merck & Co. Inc.
    • Bristol Myers Squibb Co.
    • Teva Pharmaceutical Industries Limited
    • zydus cadila
    • Novartis AG
    • F. Hoffman La Roche, Ltd.
    • Viatris Inc. (Mylan NV)
    • Cipla Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Antivirals
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Immune Modulators
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Male
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
    • 5.2.4 Male Chronic Hepatitis B (CHB) Market by Age Group
      • 5.2.4.1 Adult Market size and forecast, by region
      • 5.2.4.2 Geriartic Market size and forecast, by region
  • 5.3 Female
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
    • 5.3.4 Female Chronic Hepatitis B (CHB) Market by Age Group
      • 5.3.4.1 Adult Market size and forecast, by region
      • 5.3.4.2 Geriartic Market size and forecast, by region

CHAPTER 6: CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug Stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: CHRONIC HEPATITIS B (CHB) MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Class
    • 7.2.3 North America Market size and forecast, by Gender
      • 7.2.3.1 North America Male Chronic Hepatitis B (CHB) Market by Age Group
      • 7.2.3.2 North America Female Chronic Hepatitis B (CHB) Market by Age Group
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug Class
      • 7.2.5.1.2 Market size and forecast, by Gender
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug Class
      • 7.2.5.2.2 Market size and forecast, by Gender
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug Class
      • 7.2.5.3.2 Market size and forecast, by Gender
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Class
    • 7.3.3 Europe Market size and forecast, by Gender
      • 7.3.3.1 Europe Male Chronic Hepatitis B (CHB) Market by Age Group
      • 7.3.3.2 Europe Female Chronic Hepatitis B (CHB) Market by Age Group
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug Class
      • 7.3.5.1.2 Market size and forecast, by Gender
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug Class
      • 7.3.5.2.2 Market size and forecast, by Gender
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug Class
      • 7.3.5.3.2 Market size and forecast, by Gender
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug Class
      • 7.3.5.4.2 Market size and forecast, by Gender
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug Class
      • 7.3.5.5.2 Market size and forecast, by Gender
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug Class
      • 7.3.5.6.2 Market size and forecast, by Gender
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
    • 7.4.3 Asia-Pacific Market size and forecast, by Gender
      • 7.4.3.1 Asia-Pacific Male Chronic Hepatitis B (CHB) Market by Age Group
      • 7.4.3.2 Asia-Pacific Female Chronic Hepatitis B (CHB) Market by Age Group
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Drug Class
      • 7.4.5.1.2 Market size and forecast, by Gender
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Drug Class
      • 7.4.5.2.2 Market size and forecast, by Gender
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Drug Class
      • 7.4.5.3.2 Market size and forecast, by Gender
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Drug Class
      • 7.4.5.4.2 Market size and forecast, by Gender
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug Class
      • 7.4.5.5.2 Market size and forecast, by Gender
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug Class
      • 7.4.5.6.2 Market size and forecast, by Gender
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Class
    • 7.5.3 LAMEA Market size and forecast, by Gender
      • 7.5.3.1 LAMEA Male Chronic Hepatitis B (CHB) Market by Age Group
      • 7.5.3.2 LAMEA Female Chronic Hepatitis B (CHB) Market by Age Group
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug Class
      • 7.5.5.1.2 Market size and forecast, by Gender
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug Class
      • 7.5.5.2.2 Market size and forecast, by Gender
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug Class
      • 7.5.5.3.2 Market size and forecast, by Gender
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug Class
      • 7.5.5.4.2 Market size and forecast, by Gender
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 GlaxoSmithKline (GSK)
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Gilead Sciences, Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Merck & Co. Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Bristol Myers Squibb Co.
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Teva Pharmaceutical Industries Limited
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 zydus cadila
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Novartis AG
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 F. Hoffman La Roche, Ltd.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Viatris Inc. (Mylan NV)
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Cipla Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제